logo
TowBoatUS expands to Rocky Point area of Lake of the Woods

TowBoatUS expands to Rocky Point area of Lake of the Woods

Yahoo14-06-2025
Jun. 14—ROOSEVELT, Minn. — Boaters on the U.S. side of Lake of the Woods now have one more option if they have boat trouble on the big lake. TowBoat US 24/7 just added its second on-the-water towing and assistance service on Lake of the Woods, this one in the Rocky Point area on the west side of the lake.
Opened by Capt. Doug and Melanie Nelson of Baudette, Minnesota,
TowBoatUS Rocky Point
provides professional on-the-water towing, soft ungrounding, battery jump and fuel drop-off services. The new service at Rocky Point is part of a network of more than 300 TowBoatUS ports nationwide.
The Nelsons opened their first Lake of the Woods port, TowBoatUS Lake of the Woods, two years ago in Baudette. In a news release, Doug Nelson said it's all about going where their services are needed, providing faster response times.
"We have a lot of possibilities," Nelson said. "Being able to service the west side of the lake efficiently from our new west-side port means shorter response times to requests for assistance. We hope to grow BoatUS membership over here by providing great service."
TowBoatUS Rocky Point has a 21-foot red response vessel fully rigged for towing and salvage homeported at Arnesen's Rocky Point Resort north of Roosevelt. All of the company's captains are U.S. Coast Guard-licensed.
The Boat Owners Association of The United States (BoatUS) offers on-water
unlimited towing memberships
for freshwater boaters and anglers — much like an auto club for recreational boat owners — for just $109 per year. Membership comes with more than
25 BoatUS benefits
, including discounts at local fuel docks and transient slips at marinas. Also included are a subscription to BoatUS Magazine, free
DSC-VHF radio registration
and more.
Separate from BoatUS on-water towing, the company also offers boat salvage services.
In an interview with the Herald, Nelson said the rate for an on-the-water service call is $250 an hour for boaters who don't have the $109 BoatUS towing membership.
"If you're up by Garden Island, that's going to be an expensive tow," Nelson said. "If you're at Long Point and we come out of Arnesens, it's not going to be too bad. It does vary widely on the expense, but it can get up to $1,000 to $1,200, depending on the length of the tow. So, the $109 membership makes a ton of sense.
"We want to be able to take care of people, and then at the end of the tow, I would rather just wave and wish them a great day and not have to take their money because they're a member."
The Baudette location, now in its third season, is at the Lake of the Woods Campground marina on the Rainy River, Nelson says. Calls vary, he says, all the way from someone miscalculating and running out of gas coming back from the north end of the lake, to dead batteries, engine trouble or grounding on sandbars near Lighthouse Gap, Morris Point or Buffalo Point.
For BoatUS members who run out of gas, the only fee they have to pay is the cost of the fuel, Nelson says.
"We'll deliver fuel as a member," he said. "We'll do that for free."
Based on tows to date, the company is on pace to respond to about 60 calls this summer on Lake of the Woods, Nelson said.
"Obviously, our weekends are the busiest," he said. "We'll do several tows in a day on a nice weekend. ... And it keeps growing every year as more people know about us and memberships increase."
The company also has worked with the Lake of the Woods County Sheriff's Department to assist with boaters who need help, he said.
"We're not search and rescue — that is not our job," Nelson said "Because we're here on the lake, we can get out to a swamped boat a whole lot faster than they can."
Nelson and his wife, who also manage the marina at Lake of the Woods Campground and offer boat rentals, own their rescue boats but have a licensing agreement with TowBoatUS, which in turn provides branding, marketing and dispatching support, he said.
"They are the largest marine assist company in the United States, but we are locally owned," Nelson said. "We own the boats and we provide the captains."
To request on-the-water assistance, boaters can call the BoatUS toll-free 24/7 Dispatch Center at (800) 391-4869, call TowBoatUS Rocky Point or TowBoatUS Lake of the Woods directly at (218) 434-0087, or hail on VHF radio Channel 16.
The company also is certified through ACAPT, the Accredited for Commercial Assistance and Professional Towing organization, Nelson said.
"I think the biggest thing that we provide is the peace of mind that when you leave the dock, there's someone there, 24 hours a day, seven days a week," he said. "We've got your back if anything goes wrong."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Douglas Elliman (DOUG) Q2 EPS Misses by $0.09, Revenue Declines 5%
Douglas Elliman (DOUG) Q2 EPS Misses by $0.09, Revenue Declines 5%

Yahoo

time5 days ago

  • Yahoo

Douglas Elliman (DOUG) Q2 EPS Misses by $0.09, Revenue Declines 5%

Douglas Elliman Inc. (NYSE:DOUG) is one of the best NYSE penny stocks to invest in now. On July 31, the company announced its Q2 2025 earnings, with several key figures falling short of expectations. The quarter's revenue reached $271.4 million, a 5% decline from Q2 2024. The company recorded a net loss of $22.7 million, or $0.27 per diluted share, significantly wider than the $1.7 million loss, or $0.02 per share, in the second quarter of 2024. Africa Studio/ During the quarter, Douglas Elliman's earnings per share (EPS) missed expectations by $0.09, reporting an EPS loss of $0.06 compared to a forecast of $0.03. Adjusted EBITDA also showed a loss of $0.8 million compared to a positive $2.9 million in the same quarter of the previous year. Operating loss increased slightly to $5.5 million from $3.7 million in Q2 2024. The company stated that the revenue decline was due to a reduction in closing transactions in May and early June 2025. Despite the challenging quarter, the company cited a strong cash position of $136 million in cash and equivalents as of June 30, 2025. It also continues to invest strategically in key growth markets and agent support. Douglas Elliman Inc. (NYSE:DOUG) is an American residential real estate brokerage specializing in luxury markets across New York, Florida, California, and other high-end regions. It operates through its subsidiary, Douglas Elliman Realty, LLC, which provides brokerage services, development marketing, and ancillary offerings, including mortgage and title services. While we acknowledge the potential of DOUG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Low-Priced Stocks to Buy Right Now and 11 Best Canadian Gold Stocks to Buy According to Hedge Funds. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Business Wire

time6 days ago

  • Business Wire

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) ('Zura Bio' or the 'Company'), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. 'The second quarter of 2025 marked continued progress across our clinical programs and organizational goals,' said Robert Lisicki, Chief Executive Officer of Zura Bio. 'We advanced our Phase 2 clinical study in systemic sclerosis and initiated a second Phase 2 clinical study in hidradenitis suppurativa. We also welcomed a new Chief Financial Officer as well as a new member of our board of directors, who bring valuable experiences and perspectives. As we look ahead, we remain focused on executing our strategy with discipline and care.' PIPELINE HIGHLIGHTS AND UPCOMING ANTICIPATED MILESTONES Tibulizumab Hidradenitis suppurativa In the second quarter of 2025, Zura Bio initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe HS. A topline data readout is anticipated in the third quarter of 2026. Systemic sclerosis The Company also continued to advance TibuSURE, a global Phase 2 clinical study evaluating tibulizumab in adults with SSc. A topline data readout is anticipated in the fourth quarter of 2026. Crebankitug Zura Bio continues to conduct preclinical and translational research on crebankitug to explore its potential in immune-mediated diseases where dual inhibition of interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP) may offer therapeutic benefit. The Company is collaborating with academic researchers to guide future development decisions. Torudokimab Zura Bio is evaluating the potential role of torudokimab in inflammatory and respiratory diseases. The Company continues to monitor external clinical data from ongoing IL-33/ST2-targeted programs in asthma and chronic obstructive pulmonary disease, including Phase 2b and Phase 3 trials. An additional IL-33/ST2 data readout is expected in 2026. These findings may help inform future development plans for torudokimab. CORPORATE HIGHLIGHTS In May 2025, Dan Becker, M.D., Ph.D. joined the Board of Directors, bringing a strong background in immunology and biotechnology. In July 2025, Eric Hyllengren was appointed as Chief Financial Officer. With more than 20 years of experience in financial leadership within the life sciences sector, Mr. Hyllengren will help guide the Company's financial and operational planning. SECOND QUARTER 2025 FINANCIAL RESULTS Cash Position As of June 30, 2025, Zura Bio had cash and cash equivalents of $154.5 million. The Company anticipates that its existing cash and cash equivalents should be sufficient to support operations as currently planned through 2027. Research and Development (R&D) Expenses R&D expenses were $8.7 million for the second quarter of 2025, compared to $5.5 million for the same period in 2024. The increase of $3.2 million was primarily related to our continued advancement of our Phase 2 clinical studies evaluating tibulizumab in SSc and HS. Specifically, we incurred a $3.3 million increase in costs related to our SSc and HS clinical studies driven by an increase in contract research organization (CRO) expenses. These increases were partially offset by a $1.3 million reduction in manufacturing costs for our product candidates. R&D compensation costs increased by $0.7 million, reflecting additional headcount to support the growing development organization. General and Administrative (G&A) Expenses G&A expenses were $9.4 million for the second quarter of 2025, compared to $6.2 million for the same period in 2024. The $3.2 million year-over-year increase was primarily driven by a $2.0 million increase in compensation costs to support the expansion of administrative functions and a $1.2 million increase in external spend related to organizational growth as we continue to advance our clinical development programs. Net Loss Net loss for the second quarter of 2025 was $16.0 million, or $0.17 per share, compared to $10.3 million, or $0.17 per share, for the same period in 2024. ABOUT ZURA BIO Zura Bio is a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs. The Company's pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura Bio's lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit FORWARD-LOOKING STATEMENTS This communication includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believe,' 'predict,' 'potential,' 'continue,' 'strategy,' 'future,' 'opportunity,' 'would,' 'seem,' 'seek,' 'outlook,' 'goal,' 'mission,' and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this communication. These forward-looking statements in this release include, but are not limited to, statements regarding: Zura Bio's forecasts, including with respect to its cash resources; Zura Bio's expectations regarding funding, operating and working capital expenditures, business strategies and objectives; and expectations with respect to Zura Bio's development program, including its product candidates and the potential clinical benefits thereof, data readouts, regulatory matters, clinical studies and the design and timing thereof. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events are difficult or impossible to predict and could differ materially from those expressed or implied in such forward-looking statements, as a result of these risks and uncertainties, which include, but are not limited to: Zura Bio's expectations regarding its product candidates and their related benefits, and Zura Bio's beliefs regarding competing product candidates and products both in development and approved, may not be achieved; Zura Bio's vision and strategy may not be successful; the timing of key events and initiation of Zura Bio's studies, regulatory matters and release of clinical data may take longer than anticipated or may not be achieved at all; the potential general acceptability and maintenance of Zura Bio's product candidates by regulatory authorities, payors, physicians, and patients may not be achieved; Zura Bio's ability to attract and retain key personnel; Zura Bio's expectations with respect to its future operating expenses, capital requirements and needs for additional financing may not be achieved; Zura Bio has not completed any clinical trials, and has no products approved for commercial sale; Zura Bio has incurred significant losses since inception, and expects to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future; Zura Bio requires substantial additional capital to finance its operations, and if it is unable to raise such capital when needed or on acceptable terms, Zura Bio may be forced to delay, reduce, and/or eliminate one or more of its development programs or future commercialization efforts; Zura Bio may be unable to renew existing contracts or enter into new contracts; Zura Bio relies on third-party contract development manufacturing organizations for the manufacture of clinical materials; Zura Bio relies on contract research organizations, clinical trial sites, and other third parties to conduct its preclinical studies and clinical studies; Zura Bio may be unable to obtain regulatory approval for its product candidates, and there may be related restrictions or limitations of any approved products; Zura Bio may be unable to successfully respond to general economic and geopolitical conditions; Zura Bio may be unable to effectively manage growth; Zura Bio faces competitive pressures from other companies worldwide; Zura Bio may be unable to adequately protect its intellectual property rights; and other factors set forth in documents filed, or to be filed by Zura Bio, with the Securities and Exchange Commission (SEC), including the risks and uncertainties described in the 'Risk Factors' section of Zura Bio's Annual Report on Form 10-K for the year ended December 31, 2024, as supplemented by Zura Bio's Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025 and June 30, 2025, and other filings with the SEC. These risks and uncertainties may be amplified by health epidemics or other unanticipated global disruption events, including the conflict between Russia and Ukraine and the Israel-Hamas war and sanctions related thereto, international trade policies, including tariffs, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems, and changes in regulations, which may continue to cause economic uncertainty. Zura Bio cautions that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Zura Bio gives no assurance that it will achieve its expectations. Zura Bio does not undertake or accept any obligation to update any forward-looking statements, except as required by law. ZURA BIO LIMITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (In thousands, except share and per share data) For the Three Months Ended For the Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 8,704 $ 5,539 $ 19,178 $ 9,132 General and administrative 9,358 6,220 18,138 11,006 Total operating expenses 18,062 11,759 37,316 20,138 Loss from operations (18,062 ) (11,759 ) (37,316 ) (20,138 ) Other (income)/expense, net: Interest income (1,717 ) (2,196 ) (3,534 ) (3,411 ) Change in fair value of private placement warrants — 768 — 1,374 Other income, net (352 ) (2 ) (347 ) (25 ) Total other income, net (2,069 ) (1,430 ) (3,881 ) (2,062 ) Loss before income taxes (15,993 ) $ (10,329 ) (33,435 ) (18,076 ) Income tax benefit — — — — Net loss (15,993 ) (10,329 ) (33,435 ) (18,076 ) Accretion of redeemable noncontrolling interest to redemption value — (2,337 ) — (2,337 ) Adjustment of redeemable noncontrolling interest from redemption value to carrying value — — — 7,017 Net loss attributable to Class A Ordinary Shareholders of Zura $ (15,993 ) $ (12,666 ) $ (33,435 ) $ (13,396 ) Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted $ (0.17 ) $ (0.17 ) $ (0.36 ) $ (0.22 ) Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted 94,289,954 74,947,369 93,630,719 60,930,956 Expand

Exclusive: Northrop plans to quadruple chip output by 2030
Exclusive: Northrop plans to quadruple chip output by 2030

Axios

time13-08-2025

  • Axios

Exclusive: Northrop plans to quadruple chip output by 2030

There's a chip factory tucked between Baltimore city limits and BWI Airport. For something so high-profile, it's easy to miss. Why it matters: Northrop Grumman's Advanced Technology Lab in Linthicum Heights, Maryland, is pumping out precious, microscopic components at a time of surging stateside demand, questionable defense-industrial base fitness and broader international aggression. The company's chips can be found in F-16 and E-7 aircraft, Apache helicopters, G/ATOR radars, naval electronic warfare systems, drones, the James Webb telescope and more. Driving the news: Axios toured the lab — sterile "bunny suit" and all — in late July. The intrigue: Northrop is positioning itself as a domestic expert that plays well with others, including other defense contractors. That means greater supply chain visibility for buyers and users as well as cooperation with competitors. "The company sees a lot of value in us being able to supply our microelectronics capabilities to benefit the national interest. That's national security. That's economic security," David Shahin, senior manager of Northrop's microelectronics center, said in an interview. Zoom in: The company is bullish on advanced packaging, a process that consolidates component footprints, ultimately saving space and boosting performance. Think of it like mixed-use versus single-family residential zoning. "The promise of advanced packaging for microelectronics is now you can fabricate the best chips wherever you need to," Shahin said, "and you can join them together into something that puts the whole system ... into something that is a fraction of the size."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store